Probi AB (OSTO:PROB) EPS (Diluted) : kr-0.05 (TTM As of Mar. 2024)

View and export this data going back to 1998. Start your Free Trial

What is Probi AB EPS (Diluted)?

Probi AB's Earnings per Share (Diluted) for the three months ended in Mar. 2024 was kr0.16. Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 was kr-0.05.

Probi AB's EPS (Basic) for the three months ended in Mar. 2024 was kr0.16. Its EPS (Basic) for the trailing twelve months (TTM) ended in Mar. 2024 was kr-0.05.

Probi AB's EPS without NRI for the three months ended in Mar. 2024 was kr0.16. Its EPS without NRI for the trailing twelve months (TTM) ended in Mar. 2024 was kr-0.05.

During the past 12 months, Probi AB's average EPS without NRIGrowth Rate was -101.20% per year. During the past 3 years, the average EPS without NRIGrowth Rate was -43.30% per year. During the past 5 years, the average EPS without NRI Growth Rate was -24.60% per year. During the past 10 years, the average EPS without NRI Growth Rate was 1.70% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

During the past 13 years, Probi AB's highest 3-Year average EPS without NRI Growth Rate was 90.30% per year. The lowest was -43.30% per year. And the median was 9.60% per year.

Probi AB EPS (Diluted) Historical Data

The historical data trend for Probi AB's EPS (Diluted) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Probi AB EPS (Diluted) Chart

Probi AB Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

EPS (Diluted)

Get a 7-Day Free Trial

7.54

8.14

7.30

3.57

1.48

Probi AB Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
EPS (Diluted)	Get a 7-Day Free Trial															1.69	-0.55	0.56	-0.22	0.16

Competitive Comparison of Probi AB's EPS (Diluted)

For the Drug Manufacturers - Specialty & Generic subindustry, Probi AB's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Probi AB's PE Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Probi AB's PE Ratio distribution charts can be found below:

* The bar in red indicates where Probi AB's PE Ratio falls into.

Probi AB EPS (Diluted) Calculation

EPS (Diluted) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Diluted EPS takes into account all of the outstanding dilutive securities that could potentially be exercised (such as stock options and convertible preferred stock) and shows how such an action would impact earnings per share.

Probi AB's Diluted EPS for the fiscal year that ended in Dec. 2023 is calculated as

Diluted EPS (A: Dec. 2023 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Diluted Average)
	=	(16.819	-	0)	/	11.394
	=	1.48

Probi AB's Diluted EPS for the quarter that ended in Mar. 2024 is calculated as

Diluted EPS (Q: Mar. 2024 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Diluted Average)
	=	(1.853	-	0)	/	11.394
	=	0.16

EPS (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was kr-0.05

Probi AB (OSTO:PROB) EPS (Diluted) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.

Probi AB EPS (Diluted) Related Terms

Thank you for viewing the detailed overview of Probi AB's EPS (Diluted) provided by GuruFocus.com. Please click on the following links to see related term pages.

Probi AB (OSTO:PROB) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Probi AB (OSTO:PROB) » Definitions » EPS (Diluted)

Comparable Companies

Traded in Other Exchanges

PBBIF:USA

Address

Ideongatan 1 A, Lund, SWE, SE-223 70

Website

https://www.probi.com

Probi AB is engaged in probiotic research and development, manufacturing and sales of effective and well-documented probiotics. The company's research relates to living microorganisms with scientific health benefits. The main fields of research are gut health, immune system and nutrient absorption, iron absorption, bone health and stress and recovery. It operates in Consumer Healthcare (CHC) and Functional Food (FF). The company operates in United States, Americas, excluding the United States , Sweden, EMEA, excluding Sweden, and APAC. The company's business is divided into three operating segments. These segments are based on a geographical division and consist of the regions Americas (North and South America), EMEA (Europe, Middle East and Africa) and APAC (Asia and the Pacific).

Probi AB (OSTO:PROB) Headlines

No Headlines